Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:04 AM
Ignite Modification Date:
2025-12-25 @ 4:04 AM
NCT ID:
NCT00433602
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Cytologically or histologically confirmed diagnosis of 1 of the following:
* Metastatic breast cancer
* Colorectal cancer
* Gastric cancer
* Lung cancer
* Ovarian cancer
* Pancreatic cancer
* Hormone-refractory prostate cancer
* Scheduled to undergo chemotherapy for ≥ 3 months
* Chemotherapy for colorectal, gastric, lung, ovarian, or pancreatic cancer may be administered in the neoadjuvant, adjuvant, or palliative setting
* History of deep vein thrombosis or pulmonary embolism allowed if treatment and secondary prevention of the last episode was completed prior to study entry
* Negative baseline bilateral compression ultrasonography
PATIENT CHARACTERISTICS:
* Life expectancy \> 3 months
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* More than 6 weeks since prior chemotherapy\*
* Hormonal therapy alone is not considered chemotherapy
* More than 4 weeks since prior major surgery, including surgery for cancer
* Minor surgery (e.g., implant of a port-a-cath) within the past 4 weeks allowed
* No concurrent major surgery, including surgery for cancer, during the observation period
* Radiotherapy before or during the observation period allowed
* Concurrent chemotherapy\* in combination with additional hormonal therapy allowed
* Concurrent treatment (with the exception of antithrombotic therapy) in any other clinical trial allowed
* No concurrent or scheduled use of thromboprophylaxis or any anticoagulant therapy, including any of the following:
* Parenteral anticoagulants (e.g., heparin, low molecular-weight heparin, or other agents, such as fondaparinux or bivalirudin)
* Oral anticoagulants (e.g., vitamin K antagonists)
* Thrombolytic agents
* Chronic treatment with antiplatelet agents, such as low-dose aspirin (≤ 300 mg/day) or clopidogrel allowed NOTE: \*Chemotherapy is defined as treatment with any antineoplastic agent, including biologicals
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00433602
Study Brief:
Protocol Section:
NCT00433602